ATLANTA, April 12, 2024 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
ATLANTA, April 4, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.
UCB debuts first campaign for psoriasis drug Bimzelx during Oscars
PITTSBURGH , Jan. 10, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by UCB to dispense ZILBRYSQ®, a new FDA-approved therapy for the treatment of adults with gMG who are anti-AChR antibody positive. 1
Brussels-based biopharma company UCB confirmed Thursday that it decided not to renew its membership in the industry group BIO in 2024, the second high-profile exit from the organization in recent months.
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S
UCB presents new data about the real-world experience of FINTEPLA
ATLANTA, Nov. 14, 2023 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that BIMZELX® (bimekizumab-bkzx) is commercially available for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. BIMZELX was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023.
Post Hoc Analysis Showed CIMZIA Resulted in Meaningful Efficacy for RA Patients
UCB Presents New Five-Year Data on BIMZELX in Ankylosing Spondylitis